Briggs Morrison’s little biotech Syndax concedes 2 key trial setbacks for its lead drug, as shares shrivel some more

It takes a little patience, but if you bore through some comments about how enthusiastic Syndax $SNDX CEO Briggs Morrison is about their ongoing pivotal trial in breast cancer with their lead drug, you’ll find that the therapy just failed a couple of key combination studies with two approved PD-L1s.